Trial · NCT07031700
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
NCT07031700, Phase 2, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL. Trials, record NCT07031700. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07031700
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
- NCT number
- NCT07031700
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 22 participants, estimated
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- Mosunetuzumab, Tislelizumab
- First posted
- 2025-06-22
- Last updated
- 2025-06-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | best of complete response rate (CR) | up to the end of 8/17 cycles of treatment(each cycle 21 days) | To assess the best of complete response rate (CR) at the end of treatment of Mosunetuzumab with Tislelizumab |
| Secondary | Overall Response Rate (ORR) | up to the end of 8/17 cycles of treatment(each cycle 21 days) | Objective Response Rate is defined as the proportion of subjects who achieve complete response (CR) or partial response (PR) after treatment with Mosunetuzumab and Tislelizumab, as assessed according to Lugano 2014 criteria. |
| Secondary | Duration of Response (DoR) | up to 2 years | Duration of Response is defined as the time from the first documentation of objective response (CR or PR) to the first documentation of disease progression or death from any cause, whichever occurs first. Response will be assessed per Lugano 2014 criteria. |
| Secondary | Progression-free survival (PFS) | Assessed every 3 months during follow-up, up to 2 years | Progression-Free Survival is defined as the time from initiation of study treatment to disease progression or death from any cause, whichever occurs first. |
| Secondary | OS | Assessed every 3 months during follow-up, up to 2 years | Overall Survival is defined as the time from initiation of study treatment to death from any cause. |
| Other | Identification of candidate biomarkers associated with treatment response based on RNA-seq and/or whole exome sequencing (WES) data | up to 2 years | Tumor and/or blood samples will be collected at baseline and during treatment. RNA sequencing (RNA-seq) and/or whole exome sequencing (WES) will be performed to identify gene expression signatures, somatic mutations, or pathway alterations that correlate with clinical response (e.g., CR/PR vs. SD/PD) to the combination therapy of Mosunetuzumab and Tislelizumab. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07031700
GET https://conductscience.org/api/trials/v1/NCT07031700/registered